ORIC

Company Overview — What Does Oric Pharmaceuticals, Inc. Do?

Oric Pharmaceuticals, Inc. (ORIC) is a small-cap company in the Other sector, operating within the Pharmaceutical Products industry. The stock has a market capitalization of $837M, making it a notable participant in its sector. Investors researching ORIC stock will find a comprehensive, data-driven analysis below covering valuation, profitability, growth, dividends, and peer comparisons for the Pharmaceutical Products space.

Oric Pharmaceuticals, Inc. (ORIC) Stock Rating — Avoid (April 2026)

As of April 2026, Oric Pharmaceuticals, Inc. receives a Avoid rating with a composite score of 29.8/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.ORIC ranks #4,088 out of 4,446 stocks in our coverage universe. Within the Other sector, Oric Pharmaceuticals, Inc. ranks #35 of 37 stocks, placing it in the lower half of its Other peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ORIC Stock Price and 52-Week Range

Oric Pharmaceuticals, Inc. (ORIC) currently trades at $10.15. The stock lost $0.23 (2.2%) in the most recent trading session. The 52-week high for ORIC is $14.93, which means the stock is currently trading -32.0% from its annual peak. The 52-week low is $3.90, putting the stock 160.6% above its annual trough. Recent trading volume was 2.1M shares, reflecting moderate market activity.

Is ORIC Overvalued or Undervalued? — Valuation Analysis

Oric Pharmaceuticals, Inc. (ORIC) carries a value factor score of 20/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.58x, versus the sector average of 1.35x.

At current multiples, Oric Pharmaceuticals, Inc. trades at a premium to most Other peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Oric Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

Oric Pharmaceuticals, Inc. (ORIC) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -34.7%, compared to the Other sector average of 7.7%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -32.7% versus the sector average of 2.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ORIC Debt, Balance Sheet, and Financial Health

Oric Pharmaceuticals, Inc. has a debt-to-equity ratio of 6.0%, compared to the Other sector average of 92.5%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 14.13x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $50M.

ORIC has a beta of 1.29, meaning it is more volatile than the broader market — a $10,000 investment in ORIC would be expected to move 28.8% more than the S&P 500 on any given day. The stability factor score for Oric Pharmaceuticals, Inc. is 24/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Oric Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Oric Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.47. Net income for the quarter was $-134M. Operating income came in at $-147M.

In FY 2025, Oric Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.47. Net income for the quarter was $-129M. Operating income came in at $-143M.

In Q3 2025, Oric Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.33. Net income for the quarter was $-33M. Operating income came in at $-37M.

In Q2 2025, Oric Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.47. Net income for the quarter was $-36M. Operating income came in at $-39M.

Over the past 8 quarters, Oric Pharmaceuticals, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing ORIC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ORIC Dividend Yield and Income Analysis

Oric Pharmaceuticals, Inc. (ORIC) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Other dividend stocks may want to explore other Other stocks or use the stock screener to filter by dividend yield.

ORIC Momentum and Technical Analysis Profile

Oric Pharmaceuticals, Inc. (ORIC) has a momentum factor score of 56/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 2/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ORIC vs Competitors — Other Sector Ranking and Peer Comparison

Within the Other sector, Oric Pharmaceuticals, Inc. (ORIC) ranks #35 out of 37 stocks based on the Blank Capital composite score. This places ORIC in the lower half of all Other stocks in our coverage universe. Key competitors and sector peers include Berkshire Hathaway Inc Class A (BRK.A) with a score of 53.1/100, LAKE SHORE BANCORP, INC. (LSBK) with a score of 47.9/100, Brown-Forman Corp Class A (BF.A) with a score of 47.7/100, Enhabit, Inc. (EHAB) with a score of 48.6/100, and Moog Inc Class A (MOG.A) with a score of 42.5/100.

Comparing ORIC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ORIC vs S&P 500 (SPY) comparison to assess how Oric Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

ORIC Next Earnings Date

No upcoming earnings date has been announced for Oric Pharmaceuticals, Inc. (ORIC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ORIC? — Investment Thesis Summary

The quantitative profile for Oric Pharmaceuticals, Inc. suggests caution. The quality score of 25/100 flags below-average profitability. The value score of 20/100 indicates premium valuation. High volatility (stability score 24/100) increases portfolio risk.

In summary, Oric Pharmaceuticals, Inc. (ORIC) earns a Avoid rating with a composite score of 29.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ORIC stock.

Related Resources for ORIC Investors

Explore more research and tools: ORIC vs S&P 500 comparison, top Other stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ORIC head-to-head with peers: ORIC vs BRK.A, ORIC vs LSBK, ORIC vs BF.A.